Manoj Venkat Maddali

Manoj Venkat Maddali

Auto-generated profile, based on publicly available information

Manoj Venkat Maddali

Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford Medicine, Stanford, CA, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
MMManoj V. Maddali
Manoj V. Maddali
AKAngad Kalra
Angad Kalra
MMMichael Muelly
Michael Muelly
JRJoshua Reicher
Joshua Reicher

15 August 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MMManoj V. Maddali
Manoj V. Maddali
AMAndrew R. Moore
Andrew R. Moore
PSPratik Sinha
Pratik Sinha
CNChad Newton
Chad Newton
JKJohn S. Kim
John S. Kim
JOJustin M. Oldham
Justin M. Oldham
Rationale: Idiopathic pulmonary fibrosis (IPF) causes irreversible fibrosis of the lung parenchyma. Although antifibrotic therapy can slow IPF progression, treatment response is variable. There exists a critical need to develop a precision medicine approach to IPF. Objectives: To identify and validate biologically driven molecular endotypes of IPF. Methods: Latent class analysis (LCA) was independently performed in prospectively recruited discovery (n = 875) and validation (n = 347) cohorts. Twenty-five plasma biomarkers associated with fibrogenesis served as class-defining variables. The association between molecular endotype and 4-year transplant-free survival was tested using multivariable Cox regression adjusted for baseline confounders. Endotype-dependent differential treatment response to future antifibrotic exposure was then assessed in a pooled cohort of patients naive to antifibrotic therapy at the time of biomarker measurement (n = 555). Measurements and Main Results: LCA independently identified two latent classes in both cohorts (P < 0.0001). WFDC2 (WAP four-disulfide core domain protein 2) was the most important determinant of class membership across cohorts. Membership in class 2 was characterized by higher biomarker concentrations and a higher risk of death or transplant (discovery, hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.64–2.48; P < 0.001; validation, HR, 1.95; 95% CI, 1.34–2.82; P < 0.001). In pooled analysis, significant heterogeneity in treatment effect was observed between endotypes (P = 0.030 for interaction), with a favorable antifibrotic response in class 2 (HR, 0.64; 95% CI, 0.45–0.93; P = 0.018) but not in class 1 (HR, 1.19; 95% CI, 0.77–1.84; P = 0.422). Conclusions: In this multicohort study, we identified two novel molecular endotypes of IPF with divergent clinical outcomes and responses to antifibrotic therapy. Pending further validation, these endotypes could enable a precision medicine approach for future IPF clinical trials.

1 October 2019 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
MMManoj V. Maddali
Manoj V. Maddali
NMNicky J. Mehtani
Nicky J. Mehtani
CCCaro Converse
Caro Converse
SKSunaina Kapoor
Sunaina Kapoor
PPPaul Pham
Paul Pham
MSMaunank Shah
Maunank Shah
Background: Multiple antiretroviral (ARV) regimens are effective at achieving HIV viral suppression, but differ in pill burden, side effects, barriers to resistance, and impact on comorbidities. Current guidelines advocate for an individualized approach to ARV regimen selection, but synthesizing these modifying factors is complex and time-consuming. Methods: We describe the development of HIV-ASSIST (https://www.hivassist.com), a free, online decision support tool for ARV selection and HIV education. HIV-ASSIST ranks potential ARV options for any given patient scenario using a composite objective of achieving viral suppression while maximizing tolerability and adherence. We used a multiple-criteria decision analysis framework to construct mathematical algorithms and synthesize various patient-specific (eg, comorbidities and treatment history) and virus-specific (eg, HIV mutations) attributes. We then conducted a validation study to evaluate HIV-ASSIST with prescribing practices of experienced HIV providers at 4 large academic centers. We report on concordance of provider ARV selections with the 5 top-ranked HIV-ASSIST regimens for 10 diverse hypothetical patient-case scenarios. Results: In the validation cohort of 17 experienced HIV providers, we found 99% concordance between HIV-ASSIST recommendations and provider ARV selections for 4 case-scenarios of ARV-naive patients. Among 6 cases of ARV-experienced patients (3 with and 3 without viremia), there was 84% and 88% concordance, respectively. Among 3 cases of ARV-experienced patients with viremia, providers reported 20 different ARV selections, suggesting substantial heterogeneity in ARV preferences in clinical practice. Conclusions: HIV-ASSIST is a novel patient-centric educational decision support tool that provides ARV recommendations concordant with experienced HIV providers for a diverse set of patient scenarios.

5 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ASAartik Sarma
Aartik Sarma
SCStephanie A. Christenson
Stephanie A. Christenson
BZBeth Shoshana Zha
Beth Shoshana Zha
APAngela Oliveira Pisco
Angela Oliveira Pisco
LNLucile P.A. Neyton
Lucile P.A. Neyton
CCCarolyn S. Calfee
Carolyn S. Calfee
Background: Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and responses to therapy have been identified. Classification as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Differences in pulmonary biology underlying these phenotypes are unknown. Methods: We analyzed tracheal aspirate (TA) RNA sequencing (RNASeq) data from 41 ARDS patients and 5 mechanically ventilated controls to assess differences in lung inflammation and repair between ARDS phenotypes. In a subset of subjects, we also analyzed plasma proteomic data. We performed single-cell RNA sequencing (scRNASeq) on TA samples from 9 ARDS patients. We conducted differential gene expression and gene set enrichment analyses, in silico prediction of pharmacologic treatments, and compared results to experimental models of acute lung injury. Findings: In bulk RNASeq data, 1334 genes were differentially expressed between ARDS phenotypes (false detection rate < 0.1). Hyperinflammatory ARDS was characterized by an exaggerated innate immune response, increased activation of the integrated stress response, interferon signaling, apoptosis, and T-cell activation. Gene sets from experimental models of lipopolysaccharide lung injury overlapped more strongly with hyperinflammatory than hypoinflammatory ARDS, though overlap in gene expression between experimental and clinical samples was variable. ScRNASeq demonstrated a central role for T-cells in the hyperinflammatory phenotype. Plasma proteomics confirmed a role for innate immune activation, interferon signaling, and T-cell activation in the hyperinflammatory phenotype. Predicted candidate therapeutics for the hyperinflammatory phenotype included imatinib and dexamethasone. Interpretation: Hyperinflammatory and hypoinflammatory ARDS phenotypes have distinct respiratory tract biology, which could inform targeted therapeutic development. Funding: National Institutes of Health; University of California San Francisco ImmunoX CoLabs; Chan Zuckerberg Foundation; Genentech

11 July 2025 in Current Opinion in Pulmonary Medicine
Verified
Journal Article
Closed access
MMManoj V. Maddali
Manoj V. Maddali
JOJustin M. Oldham
Justin M. Oldham
CMCatharina C. Moor
Catharina C. Moor
Purpose of review: Interstitial lung disease (ILD) presents significant diagnostic and therapeutic challenges due to underlying biological heterogeneity and variable clinical course. Traditional diagnostic and prognostic tools are limited in their ability to capture this heterogeneity or guide personalized treatment. Advances in biological phenotyping have set the stage for precision medicine in ILD, improving diagnosis, prognosis, and therapeutic decision-making in ILD. This review highlights recent advances in biological phenotyping technologies and their potential to reshape ILD care. Recent findings: Emerging evidence supports the use of genomic, transcriptomic, and proteomic, and metabolomic biomarkers to identify distinct ILD subgroups with prognostic or therapeutic relevance. Several biomarkers are being evaluated prospectively, including TOLLIP genotype and eNose technology. Machine learning enables the integration of high-dimensional multiomics data, offering insights beyond what single biomarkers can provide. Summary: Precision medicine in ILD is advancing rapidly and holds promise for more individualized care. Future efforts should prioritize multimodal integration, prospective validation across diverse ILD subtypes, and translating research into clinical practice. Continued innovation and collaboration will be essential to fully realize the potential of precision medicine in transforming ILD care and research.

4 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NMNicholas P. Marshall
Nicholas P. Marshall
WCWenyuan Chen
Wenyuan Chen
FAFatemeh Amrollahi
Fatemeh Amrollahi
FHFateme Nateghi Haredasht
Fateme Nateghi Haredasht
MMManoj V. Maddali
Manoj V. Maddali
JCJonathan H Chen
Jonathan H Chen
Background: The 2024 blood culture bottle shortage brought diagnostic resource allocation to the forefront, reflecting persistent, foundational challenges with low-value testing and empiric treatment approaches under clinical uncertainty. Objective: To determine whether a machine learning approach using electronic medical record data can predict bacteremia more effectively than existing systems and practices to guide diagnostic testing and empiric treatment strategies. Methods: In a retrospective cohort of 101,812 adult emergency department encounters (2015-2025), we first established an idealized cognitive baseline by evaluating physician and generative AI (GPT-5) application of the professional society-endorsed Fabre framework on a validation subset. We then trained an XGBoost model (Cultryx) on the full cohort to predict bacteremia, benchmarking its performance against real-world clinical heuristics (SIRS, Shapiro Rule). Results: For the idealized baseline, physicians applying the Fabre framework achieved 95.7% sensitivity, but GPT-5 automation failed to replicate this standard (71.6% sensitivity). In real-world benchmarking, Cultryx outperformed all clinical heuristics (AUROC 0.810). SIRS lacked specificity (41.2%), driving diagnostic overuse, while the Shapiro Rule lacked sensitivity (70.2%), missing ~30% of bacteremia cases. In contrast, when calibrated to a strict 95% sensitivity target, Cultryx achieved the highest culture volume deferral rate (26.2%, deferring ~ 15,872 bottles with predicted negative results) while maintaining a 98.9% negative predictive value. Cultryx score , a simplified bedside tool, retained a 20.8% deferral rate. Conclusions: Machine learning provides a superior, data-driven alternative to mainstream clinical heuristics for predicting bacteremia. By maximizing culture deferment without compromising pathogen detection, Cultryx can conserve diagnostic resources, reduce unnecessary empiric antibiotic exposure, and systematically elevate patient safety. Summary: Cultryx, a machine learning model for blood culture stewardship, outperforms standard clinical heuristics in predicting bacteremia. This approach could reduce culture utilization by over 26% while preserving pathogen detection, conserving diagnostic resources, reducing unnecessary antibiotic exposure, and elevating patient safety.